IGBA Kicks Off Biosimilars Week
Educational Resources Have Been Made Available By The Global Association
A week-long global educational initiative to raise awareness of biosimilars has been launched by the IGBA.
You may also be interested in...
The IGBA has followed the success of its inaugural Global Biosimilars Week in November 2020 by launching the second incarnation of the initiative, running this week.
An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.
In an exclusive interview with Generics Bulletin, IGBA chair Sudarshan Jain said that a resilient and diversified supply chain is critical, but localized production may not be the answer to everything. IGBA secretary general Suzette Kox and Jain discussed key lessons to be learned from COVID-19, the IGBA’s focus on regulatory harmonization, and challenges in driving the adoption of generics, biosimilars and value-added medicines.